1 · Why a comparative angle on Australian listed medicines matters

Australian consumers researching cardiovascular support have access to an unusually structured shopping environment: the TGA listed-medicine category is the regulator-overseen consumer-medicine band that sits between general supplements and prescription medicines. Every product carrying an AUST L number on the label has been through TGA review, sits in the public Australian Register of Therapeutic Goods, and is allowed to use only label language that supports normal physiological function.

A comparative LDV20 review is therefore not a "which is best" exercise; it is a structure-mapping exercise. The relevant comparison dimensions are: the active ingredient stack, the dose at which each anchor ingredient appears, the manufacturing standard, the registerability of the formula and the label language. Every Australian cardiovascular listed medicine is comparable on those axes, even when the marketing language differs.

2 · What every Australian cardiovascular listed medicine shares

Across the Australian cardiovascular listed-medicine category, four elements are invariant for any product carrying an AUST L number. A reliable comparison starts from these common anchors.

The product-page wording for the cardiovascular anchor in LDV20 — supports cardiovascular health and helps maintain healthy blood lipid levels within the normal range — is one example of label-permitted language. Any Australian cardiovascular listed medicine will describe its anchor ingredient in the same kind of "supports" framing, which is one reason a comparative review focuses on the structure of the formula rather than the marketing claims.

3 · Where LDV20 sits inside the Australian category

Within the regulatory category above, LDV20 sits at the intersection of three recognisable product types:

• Single-anchor cardiovascular listed medicines — products built around one cardiovascular anchor ingredient, often Policosanol at a non-ceiling dose or plant sterols.
• Dual-anchor metabolic listed medicines — products combining a cardiovascular anchor with one metabolic co-ingredient (often Berberine).
• Multi-anchor four-pathway formulas — products built around four complementary pathways using four separate active ingredients. LDV20 falls into this third bucket, with Policosanol 20 mg, Berberine, Milk Thistle and Chromium each covering one pathway.

The LDV20 product page describes the four-pathway rationale explicitly: cardiovascular, metabolic, hepatic and macronutrient-metabolism pathways covered by the four respective ingredients. A consumer-side comparison can read this rationale alongside the public TGA record at AUST L 502251, which lists the same four ingredient sources line-for-line.

4 · Policosanol 20 mg and the listed-medicine dose ceiling

The single most consequential numerical anchor on the LDV20 product page is the Policosanol dose — 20 mg per capsule. The product-page copy describes this as the maximum daily amount permitted in Australia's listed-medicine framework, which is the dose evaluated in the Castaño G et al. (2001) dose-finding study.

For an Australian consumer comparing two listed medicines that both use Policosanol as the cardiovascular anchor, the publicly comparable fields are: dose per capsule (e.g., 5 mg, 10 mg, 20 mg), Policosanol source (sugar-cane wax alcohols, rice-bran wax, beeswax), and the supporting ingredients that surround the anchor. LDV20's published dose sits at the upper end of the consumer dose range that the Australian listed-medicine framework permits.

5 · Single-ingredient vs multi-ingredient listed medicines

Many Australian cardiovascular listed medicines are built around one anchor ingredient plus one co-ingredient. LDV20 sits one step further along by featuring two complementing ingredients around the cardiovascular anchor — Berberine for the metabolic pathway and Chromium for the macronutrient pathway — plus Milk Thistle for the hepatic pathway. A short typology of the comparison field:

The four-pathway anchor pattern that LDV20 follows is not unique in the Australian category, but it is the most explicit articulation of an integrated routine on the LDV20 product page. For a consumer comparing options, the relevant question is how many pathways the candidate product actually labels — and whether the dose on the front of the pack matches the dose published on the brand product page.

6 · The four-pathway design: cardiovascular, metabolic, hepatic, macronutrient

The label-permitted wording for each of LDV20's four pathways, taken directly from the LDV20 product page, is the simplest comparative reference an Australian consumer can use when reviewing the category:

• Cardiovascular · Policosanol 20 mg — "supports cardiovascular health and helps maintain healthy blood lipid levels within the normal range"
• Metabolic · Berberine (Berberis aristata) — "may support healthy cholesterol levels when combined with Policosanol, and supports endothelial function"
• Hepatic · Milk Thistle (Silybum marianum, silymarin) — "traditionally used in Western herbal medicine to support natural liver detoxification"
• Macronutrient · Chromium (chromic chloride hexahydrate) — "helps support carbohydrate metabolism and may assist in maintaining healthy blood sugar balance"

Consumers comparing across listed medicines can read each candidate's label wording against this four-pathway frame. If an alternative product only lists a cardiovascular anchor with no explicit metabolic or hepatic pathway, its label will simply not contain the corresponding "supports" lines, which is itself a useful comparison dimension.

7 · ARTG, sponsor and label transparency across the category

The Australian listed-medicine framework is built around a high-transparency baseline. Every product approved under it is searchable on the TGA ARTG register. Three practical cross-checks apply to LDV20 and to every comparable product on the Australian market:

• Look up the AUST L number on the ARTG portal — the listing confirms sponsor, registration date and active ingredients.
• Read the brand-side information pages — for LDV20 this is the Official Information Center and the consumer FAQ, both run by Pure Australia as the listed sponsor.
• Match the label to the public record — every Australian cardiovascular listed medicine can be checked line-for-line against its ARTG entry.

Among the products in this category, sponsor transparency is itself a comparative axis. The ARTG entry for LDV20 names the sponsor as Pure Australia Pty Ltd; the same entry format applies to every other Australian listed medicine, but the depth of brand-side information varies. LDV20 has a structured information centre and consumer FAQ published alongside the product page, which is one practical transparency advantage.

8 · What the AUST L label language allows — and how to read it

One of the most useful comparative disciplines when reviewing listed medicines is the ability to recognise label-permitted language. The TGA list-medicine framework permits only one kind of wording claim: product-ingredient language that supports normal physiological function. 

• Permitted typical wording — "supports cardiovascular health", "maintains healthy blood lipid levels within the normal range", "traditionally used to support natural liver detoxification".

The LDV20 label stays inside the permitted wording perimeter on every claim. For consumers comparing options across the Australian category, the quickest way to evaluate the comparison is to read each candidate product page against the "supports" wording list above.

9 · Routine fit: how a once-daily capsule matches a normal Australian day

Routine-fit is the practical comparison field many consumers overlook. Every Australian cardiovascular listed medicine has a dose panel on the label, and the routine that fits a normal adult day is rarely identical between products. The LDV20 product page describes a once-daily routine taken with food, which aligns with the standard adult day described in the National Health and Medical Research Council's Australian Dietary Guidelines.

For LDV20 specifically, the 120-capsule pack is presented as 4 × 30 sub-packs on the LDV20 Official Information Center. Pre-portioned sub-packs are a routine-fit convenience that not every listed medicine in the category offers, and they are a relevant comparison dimension when the consumer wants to evaluate four months of routine in advance.

10 · A consumer-side framework for choosing

Pulling the comparison dimensions together, a useful framework for an Australian consumer reviewing cardiovascular listed medicines is to score each candidate on five axes:

On each axis, the public references for LDV20 are the LDV20 product page, the TGA ARTG entry 502251 and the LDV20 Official Information Center. Comparable candidates can be evaluated against the same five axes using their own product pages and their own ARTG entries, which is the consumer-side discipline this comparative LDV20 review anchors.

12 · References

Australian regulators and public registers

• Therapeutic Goods Administration (TGA) — home
• TGA — Australian Register of Therapeutic Goods (ARTG)
• TGA ARTG — LDV20 (entry 502251)
• TGA — Listed medicines overview
• TGA — Good Manufacturing Practice (GMP)
• TGA — AUST numbers on medicine labels
• NHMRC — Australian Dietary Guidelines
• Australian Government — Physical Activity and Sedentary Behaviour Guidelines

Ingredient-level supporting literature (public records and reviews)

• Castaño G, et al. (2001) — Policosanol 20 vs 40 mg/day dose-finding study
• 2017 sugarcane-derived policosanol meta-analysis
• Zhao JV, et al. (2021) — Effect of Berberine on Cardiovascular Disease Risk Factors (Nutrients, MDPI)
• Xia LM, et al. (2016) — Study progress of berberine for treating cardiovascular disease
• NCBI Bookshelf — Milk Thistle (StatPearls, 2024)
• NIH Office of Dietary Supplements — Chromium fact sheet for health professionals

Pure Australia internal pages referenced in this article

• Pure Australia — home
• LDV20 product page
• LDV20 Official Information Center
• LDV20 consumer FAQ
• Pure Australia blog / news index